In recent years, the field of cancer research has witnessed a growing interest in targeting RNA editing as a potential therapeutic strategy. Adenosine Deaminase Acting on RNA (ADAR), a key enzyme involved in RNA editing, has emerged as an attractive target for cancer therapy. In this blog post, we will explore the role of ADAR and RNA editing in cancer and the potential of ADAR inhibitors as effective cancer therapeutics, highlighting the progress made in this area and the challenges that lie ahead.
